Physician profile
William A Kaye
NPI 1003820002
$514,687.07
in general payments reported to CMS, 2019-2025
63 companies · $100K in 2025
The $100K reported for 2025 was more than what 98% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $59K · 2020: $33K · 2021: $45K · 2022: $69K · 2023: $92K · 2024: $116K · 2025: $100K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $281K · Travel and Lodging: $10K · Food and Beverage: $9,164 · Consulting Fee: $6,338 · Education: $68.76.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $281,471.44 |
| Travel and Lodging | $10,211.18 |
| Food and Beverage | $9,163.93 |
| Consulting Fee | $6,337.50 |
| Education | $68.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $246,960.50 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Novo Nordisk INC | $146,711.19 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $78,391.68 | 2019-2025 | Jardiance, Synjardy, Tradjenta |
| Astrazeneca Pharmaceuticals LP | $15,143.06 | 2019-2023 | Farxiga |
| Merck Sharp & Dohme LLC | $7,170.51 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $6,465.55 | 2021-2025 | |
| Abbvie INC. | $3,775.26 | 2019-2025 | |
| Abbott Laboratories | $1,231.46 | 2019-2025 | Freestyle Libre 3 |
| Tosoh Bioscience, INC. | $1,078.00 | 2019 | |
| Amgen INC. | $1,007.89 | 2019-2025 | Evenity, Tepezza, Repatha |
| Mannkind Corporation | $821.19 | 2019-2025 | Afrezza |
| Sanofi-Aventis U.S. LLC | $692.23 | 2019-2025 | |
| Insulet Corporation | $572.02 | 2021-2025 | Omnipod |
| Novartis Pharmaceuticals Corporation | $430.26 | 2022-2025 | |
| Xeris Pharmaceuticals, INC. | $402.74 | 2020-2025 | Gvoke Hypopen, Recorlev |
Show all 60 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $339.22 | 2024-2025 | Dexcom G7 Gss (161), Dexcom Stelo Glucose Biosensor, Dexcom G6 Transmitter |
| Antares Pharma, INC. | $298.42 | 2019-2025 | Xyosted |
| Sequel Med Tech, LLC | $259.02 | 2025 | Twiist |
| Tandem Diabetes Care, INC. | $237.65 | 2019-2024 | T:Slim X2 Insulin Pump With Control-Iq |
| Neurocrine Biosciences, INC. | $208.16 | 2024-2025 | |
| Amarin Pharma, INC. | $198.45 | 2019-2021 | |
| Medtronic, INC. | $193.10 | 2021-2023 | Minimed 780g |
| Amneal Pharmaceuticals LLC | $189.99 | 2019-2025 | Unithroid |
| Radius Health, INC. | $170.97 | 2019-2025 | Tymlos |
| Horizon Therapeutics Plc | $162.42 | 2019-2022 | |
| Beta Bionics, INC. | $145.57 | 2024 | Ilet Bionic Pancreas |
| Ipsen Biopharmaceuticals, INC | $143.81 | 2019 | |
| Vivus LLC | $127.81 | 2019-2024 | Qsymia |
| Madrigal Pharmaceuticals | $123.10 | 2025 | Rezdiffra |
| Corcept Therapeutics | $116.62 | 2023-2025 | Korlym |
| Lifescan, INC. | $111.32 | 2019-2022 | |
| Medtronic Minimed, INC. | $56.47 | 2019-2020 | |
| Alvogen INC | $54.19 | 2022-2024 | Teriparatide |
| Halozyme INC | $49.17 | 2023 | |
| Ultragenyx Pharmaceutical INC. | $47.69 | 2022-2024 | Crysvita |
| Nevro Corp. | $44.50 | 2022-2023 | Senza |
| Ascendis Pharma Endocrinology INC | $42.66 | 2023-2025 | Yorvipath |
| Pfizer INC. | $39.90 | 2023-2024 | |
| Verity Pharmaceuticals INC. | $37.21 | 2024 | Tlando |
| Sanofi Pasteur INC. | $36.37 | 2020-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $33.98 | 2020-2021 | |
| Recordati_rare_diseases_inc. | $32.91 | 2021-2025 | Isturisa |
| Quidel Corporation | $32.32 | 2019 | |
| Globus Medical, INC. | $28.06 | 2025 | Senza |
| Acerus Pharmaceuticals Corporation | $27.11 | 2020-2022 | |
| Averitas Pharma INC. | $23.85 | 2024 | Qutenza |
| Astellas Pharma US INC | $21.62 | 2025 | Veozah |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $21.17 | 2019 | |
| Shire North American Group INC | $20.63 | 2019 | |
| Vanda Pharmaceuticals INC. | $18.19 | 2020 | |
| Kyowa Kirin, INC. | $17.26 | 2024 | Crysvita |
| Alnylam Pharmaceuticals INC. | $17.05 | 2020 | |
| Tolmar, INC. | $15.07 | 2023 | |
| Vistapharm, INC. | $14.98 | 2021 | |
| Esperion Therapeutics, INC. | $14.01 | 2020 | |
| Amryt Pharma Holdings LTD | $13.96 | 2022 | |
| Companion Medical, INC. | $13.28 | 2020 | |
| Cardiovascular Systems INC. | $11.96 | 2019 | |
| Acella Pharmaceuticals, LLC | $11.49 | 2019 | |
| Nalpropion Pharmaceuticals LLC | $10.84 | 2019 |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Kaye listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.